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The vertebrate skeleton forms via two distinct modes of ossification, membranous and endochondral.
Osteoblasts are also heterogeneous in embryonic origin; bone formed by either mode can be derived from
neural crest cells or mesoderm. In contrast, all bone develops via a common genetic pathway regulated
by the transcription factor Runx2. Runx2 is required for bone formation, and haploinsufficiency in humans
causes the skeletal syndrome cleidocranial dysplasia, demonstrating the importance of gene dosage.
Despite the central role of Runx2 in directing bone formation, little is understood about how its expression
is regulated in development. We took an unbiased approach to identify direct regulatory inputs into Runx2
transcription by identifying cis-regulatory elements associated with the human gene. We assayed
conserved non-coding elements in a 1 Mb interval surrounding the gene for their ability to direct
osteoblast expression in transgenic zebrafish. We identified three enhancers spaced out across the
interval. Within each we identified conserved transcription factor binding sites required for their activity,
and further showed distinct and specific regulation of each. The enhancer in the last intron of RUNX2
itself is positively regulated by the FGF signaling pathway, an enhancer in the last intron of the adjacent
gene, SUPT3H, is regulated by canonical Wnt signaling, and a distant downstream enhancer requires a
conserved Dlx binding site for its activity. While all of these pathways and factors have been previously
implicated in bone formation, our results provide the first direct links to the common genetic pathway
regulating osteogenesis, transcription of Runx2. These findings further illustrate the integration of
multiple regulatory inputs at the level of transcription of a key developmental gene, and highlight the role
of Runx2 as the gatekeeper for changes in skeletal morphology achieved through alterations in gene
expression.
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ABSTRACT

MULTIPLE CONSERVED ENHANCERS OF THE OSTEOBLAST MASTER
TRANSCRIPTION FACTOR, RUNX2, INTEGRATE DIVERSE SIGNALING
PATHWAYS TO DIRECT EXPRESSION TO DEVELOPING BONE
Christopher William Weber
Shannon Fisher
The vertebrate skeleton forms via two distinct modes of ossification,
membranous and endochondral. Osteoblasts are also heterogeneous in
embryonic origin; bone formed by either mode can be derived from neural crest
cells or mesoderm. In contrast, all bone develops via a common genetic pathway
regulated by the transcription factor Runx2. Runx2 is required for bone
formation, and haploinsufficiency in humans causes the skeletal syndrome
cleidocranial dysplasia, demonstrating the importance of gene dosage. Despite
the central role of Runx2 in directing bone formation, little is understood about
how its expression is regulated in development. We took an unbiased approach to
identify direct regulatory inputs into Runx2 transcription by identifying cis–
regulatory elements associated with the human gene. We assayed conserved
non-coding elements in a 1 Mb interval surrounding the gene for their ability to
direct osteoblast expression in transgenic zebrafish. We identified three
enhancers spaced out across the interval. Within each we identified conserved
transcription factor binding sites required for their activity, and further showed
iv

distinct and specific regulation of each. The enhancer in the last intron of
RUNX2 itself is positively regulated by the FGF signaling pathway, an enhancer
in the last intron of the adjacent gene, SUPT3H, is regulated by canonical Wnt
signaling, and a distant downstream enhancer requires a conserved Dlx binding
site for its activity. While all of these pathways and factors have been previously
implicated in bone formation, our results provide the first direct links to the
common genetic pathway regulating osteogenesis, transcription of Runx2. These
findings further illustrate the integration of multiple regulatory inputs at the
level of transcription of a key developmental gene, and highlight the role of
Runx2 as the gatekeeper for changes in skeletal morphology achieved through
alterations in gene expression.
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CHAPTER 1
INTRODUCTION
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CHAPTER 1
Characteristics of the vertebrate skeleton
The presence of a mineralized endoskeleton is one of the common features
of the vertebrate lineage 1 . In addition to its historically understood roles in
support and as the sites of muscle attachment, the skeleton has more recently
been understood to be the site of hematopoiesis 2 , endocrine regulation of glucose
metabolism 3 , a reservoir for inorganic minerals 4 and critical in male
reproductive function 5 .
The vertebrate skeleton is chiefly composed of two tissue types: bone and
cartilage.a Cartilage is the more evolutionarily primary of the two 6 . While not
possessing a ‘true’ skeleton, the chordate amphioxus expresses orthologs of
cartilage marker genes in the nascent notochord 7 . Cartilage is composed of
chondrocytes suspended in a rigid matrix rich in collagen fibrillar proteins and
acidic polysaccharides 8 . The most abundant of these proteins are type II
collagen and aggrecan, whose negative charge accounts for the osmotic swelling
of the tissue 9 , resulting in the familiar rigid plasticity of the material. This
property confers a biomechanical role in the fully realized skeleton, allowing
articular surfaces of joints to tolerate compressive forces.
Conversely, bone is vascularized, has a higher metabolic activity and
differs in its extracellular matrix (ECM) composition both in the content of
secreted proteins, but also in the presence of inorganic calcium 10 . Unlike the

Two other tissue types found exclusively in teeth are dentin and enamel, though
they will not be discussed further in this document.
2
a

cartilage ECM, 90% of the total dry protein weight is type I collagen. Collagen I
forms an extensively crosslinked fiber, around which calcium crystals in the form
of spindles of hydroxyapatite are deposited, resulting in the characteristic
rigidity of bone tissue 11 . Other well-characterized components include alkaline
phosphatase, osteopontin, and osteocalcin 12 .
Osteoblasts are the cells responsible for the deposition of this defining
matrix. Correspondingly, they have a highly basophilic cytoplasm and extensive
endoplasmic reticulum and Golgi apparatus 13 to produce substantial amounts of
secreted protein. Following matrix deposition, osteoblasts either become lining
cells or remain embedded in bone, the latter defined as osteocytes 14 . These cells
account for 95% of mature bone tissue. Another bone cell type, osteoclasts,
arises from the monocytic/macrophage lineage postnatally 15 . These cells have a
resorbative role in bone homeostasis and therefore regulate bone mass density.
Embryonic origins of the vertebrate skeleton
Skeletogenesis describes the process by which mesenchymal stem cells
(MSCs) differentiate into osteoblasts and chondrocytes in a defined program.
MSCs are loose, multipotent cells with the capacity to differentiate into nonskeletal cell types such as adipocytes or myocytes 16 . Whether commitment to
the skeletal lineage involves the existence of a bipotential skeletal precursor cell
type, capable of adopting a bone or cartilage fate, is at issue in the literature 17 .
Skeletal elements in the embryo forms via two distinct processes.
Intramembrous ossification describes direct condensation of migrated MSCs and
3

subsequent transformation to bone 18 . This process is employed in the creation
of the flat bones of the skull as well as fracture repair. Elsewhere, particularly in
the long bones, endochondral ossification results in the calcification and invasion
of a cartilaginous scaffold by osteoprogenitor cells 19 . A complementary
heterogeneity is observed in the embroynic origin of MSCs, where neural crest,
lateral plate, and somitic mesoderm all contribute to the developing skeleton 16 .
Genetic origins of the vertebrate skeleton – Runx2
However, this diversity contrasts with the uniform genetic origin of
skeletal tissues. Commitment to the osteoblast lineage requires the expression of
the early marker gene and runt domain containing transcription factor Runx2 20 .
The runt domain is a site of protein-protein interaction, as well as binding to the
core sequence 5’- PyGPyGGTPy-3’ 21 . Runx2 -/- mice fail to generate any
osteoblasts 22 , and chondrocyte maturation and terminal differentiation are
disturbed 23 . Additionally, haploinsufficency at the locus causes the skeletal
disorder cleidocranial dysplasia, marked by delayed closure of the fontanelles of
the skull, hypoplasticity of the clavical, and other features 24 (OMIM# 119600).
RUNX2 binds to and upregulates other osteoblast marker genes 25 , which are
also upregulated following forced expression of Runx2 in non-skeletal tissues,
including fibroblasts, C3H10T1/2 cells, primary myoblasts, and marrow stromal
cells

25-27

. For these reasons, Runx2 has been recognized as occupying an

indispensable bottleneck position in the osteoblast fate switch and is often
referred to the master regulator of osteoblast development 28 .
4

The dosage of Runx2 must be finely tuned in order to properly execute
differentiation. Overexpression of Runx2 in osteoblasts arrests bone development
in a mouse model, resulting in an osteopenic phenotype 29 . Forced expression in
chondrocytes produces precociously mature cells that produce osteoid tissue and
bone marrow not present in orthologous structures in wild type animals 30 .
Despite Runx2’s unquestioned indispensability early in fate commitment, the
notion that Runx2 might not have a role in mature osteoblasts has been
proposed, as expression of a dominant negative form of the protein exclusively in
mature osteoblasts does not affect transcription of the osteoblast marker
osteocalcin, a gene that can be activated by forced expression of Runx2 in non
osteoblastic cells 25, 31 .
Genetic origins of the vertebrate skeleton – sp7/osx
An answer to potential regulators of later osteoblast differentiation came
with the identification of Sp7/Osx as a cDNA species specifically expressed in
C2C12 cells undergoing osteoblastogenesis. Sp7 codes for a zinc fingercontaining transcription factor from the Kruppel-like factor family 32 . As with
Runx2, inactivation of in mouse models yielded a skeleton devoid of osteoblasts;
however mineralization did occur in bones formed by endochondral ossification,
though the features of those tissues were more akin to a mineralized form of
cartilage. Interestingly, Runx2 expression levels were unaffected, indicating that
Sp7 is not upstream of Runx2. Further work located Sp7 as a direct target of

5

Runx2 b. Sp7 is recruited to its own promoter in murine UMR106-01
osteosarcoma cells to the exclusion of other members of the sp transcription
factor family in a manner that correlates with the expression of sp7 33 .
Sp7 is thought to function exclusively in later osteoblast differentiation
and distinct from the activities of Runx2 in cartilage. Among Sp7’s target genes 34
are the bone marker genes Col1a1 35 , Bsp 36 and Ocn. The regulation of Col1a1
by Sp7 is corroborated clinically by a report of a proband presenting with
osteogenesis imperfecta and a frameshift mutation within the SP7 coding region
37

. Finally, in contrast to Runx2, Sp7 function appears to be critical for postnatal

growth and maintenance of bone 38 .
Molecular signaling and the vertebrate skeleton – The BMP pathway
Bone morphogenetic proteins (BMPs) were initially identified on the basis
of their ability to induce de novo bone and cartilage formation in vivo 39, 40 . Most
BMPs are members of the transforming growth factor- superfamily of proteins
with important roles in both proper patterning and differentiation of the
skeletonc. Canonically, signaling starts upon BMP ligand binding to heteromeric
cell surface receptors composed of BMPR-I and BMPR-II receptors. This
activated complex phosphorylates cytoplasmic SMAD proteins via a serinethreonine kinase domain. SMADs 1,5 and 8 bind to a co-SMAD upon
phosphorylation and enter the nucleus to directly affect gene transcription via

b
c

Allen, unpublished observation
Notably, BMP-1 is a metalloproteinase.
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chromatin binding. As will be discussed in future sections, the Smad proteins
offer a context for crosstalk with other signaling pathways.
Understanding the role of BMP signaling in skeletogenesis is complicated
by the presence of multiple components with distinct, yet overlapping, activities,
as well the necessity of BMP signaling in early embryo patterning formation.
BMP-2, --4,-6,and -7 are ligands with demonstrable osteogenic potential in vitro,
yet genetic studies using conditional knockout alleles reveal more subtle and
complementary roles. Both Bmp2 and Bmp4 activities are dispensable for the
formation of the long bones, of the limbs, though deletion of the former results in
an increase of fractures postnatally 41, 42 . Similarly, loss of Bmpr2 43 and Bmp7
have no demonstrable effect on bone formation or fracture repair in the limbs 44 .
However, a double knockout of Bmp2 and Bmp4 results in a severe impairment
of osteogenesis, indicating a redundancy in these roles 45 .
Runx2 upregulation has been observed in in vitro systems following BMP
stimulation 46, 47 , and consequently, Runx2 is thought to be the principle mediator
of downstream BMP actions 48 . However, there are also thought to be BMP
signals capable of driving osteoblastogenesis independently of Runx2. Although
BMP-2 administration is not capable of driving full differentiation of osteoblasts
and chondroblasts in Runx2-deficient mouse calvarial cell lines, upregulation of
alkaine phosphatase, osteocalcin and sp7 is detectable

22, 49, 50

. BMP-2 treatment

upregulates sp7 expression in C2C12 cells independently of Runx2 51 . Also,
preosteoblastic cell lines require autocrine BMP signaling for proper
7

differentiation, although they already express Runx2 52, 53 . Finally, activated
SMAD proteins interact physically and functionally with RUNX2, suggesting a
synergistic relationship to complement the Runx2 dependent and independent
BMP signaliing axes. SMAD1 and RUNX2 transcription factors complex to drive
gene expression on target gene promoters 54 . An osteoblast specific deletion of
Smad1 causes an osteopenic phenotype 55 , and combined deletion of Smad1/5/8
results in severe chondrodysplasia 56 .
Pretreatment with the ribosome inhibitor cyclohexamide prior to BMP-2
treatment blocks the induction of Runx2 57 and sp7 58 , indicating the need for the
synthesis of an intermediate protein to complete the signaling axis. Among the
direct targets of BMP signaling with known roles in skeletogenesis are
homeodomain proteins. In particular, microarray experiments examining the
transcriptional response to BMP-2 treatment in cultured C2C12 osteoprogenitor
cells have identified members of the meshless(Msx), distalless(Dlx), and
aristaless(Alx) transcription factor families as being immediately and transiently
induced, prior to the commitment to osteogenesis evidenced by expression of
Runx2 59-61 . Mutations associated with the Msx1 and Msx2 loci demonstrate
consequences in skeletal patterning and differentiation. Msx1-/- mice exhibit
craniofacial and tooth development abnormalities including a cleft palate
phenotype 62 , while Msx2-/- mice possess delayed calvarial bone growth, defects
in endochondrial ossification and chondrogenesis, as well as reduced expression
of osteocalcin and Runx2

63

. Simultaneous deletion of both Msx2 and Msx1
8

results in the complete absence of craniofacial bone 63, 64 A reversal of this dosage
effect is evidenced in a human MSX2 gain of function mutant with enhanced
DNA binding, eliciting a premature fusion of the calvarial sutures and
craniosynostosis 65 . Significantly, microduplications upstream of MSX2
containing many conserved non-coding elements phenocopy CCD, suggesting a
potentially rigid regulatory apparatus between BMP signaling and Runx2 in vivo
66

.
In tetrapods, members of the Dlx gene family are grouped in binary

clusters, facing each other via their 3’ ends as a result of presumptive gene
duplication events 67 . Dlx1 and Dlx4 have important roles in tooth development 68
and hematopoiesis 69 , respectively, but they have not been identified as
expressed in osteoblasts. Although Dlx3 inactivation results in embryonic
lethality, it is expressed in osteoblastic lineage cells during endochondral
ossification, and at its highest level in mature osteocalcin and Runx2 expressing
osteoblasts 70, 71 . A 4bp frameshift deletion in the human DLX3 gene causes an
autosomal dominant disease, tricho-dento-osseous syndrome (OMIM#600525),
which is characterized by altered dermal bone formation in the skull as well as
increased bone density 72 . Consistent with this observation, interaction between
DLX3 and RUNX2 reduces the capacity of RUNX2 to direct transcription at the
osteocalcin promoter in a cell culture context 73 .
Current opinion in the literature designates Dlx5 as a critical regulator of
BMP mediated osteogenesis 74 . Simultaneous knockout of the Dlx5/6 cluster
9

results in gross skeletal abnormalities, including absence of the calvaria,
maxilliary and mandibular bones, as well as a generalized ossification delay in
the axial skeleton 75 . These anomalies are also seen in Dlx5 -/- mice; curiously, no
data on a Dlx6 -/- phenotype has been published. Dlx5 induction by BMPs has
been observed in both the contexts of cell culture(MC3T3-E1 cells) 76 and in vivo
development(chick skull development) 77 , where Dlx5 expression is visible in
proliferating suture mesenchyme not yet committed to an osteoblastic fate,
suggesting a role in fate designation prior to Runx2 induction. Dlx5 induces
Runx2 in immature calvaria mesenchyme culture 78 , and Dlx5 and Runx2 have
been shown to be recruited together at the stimulated promoters of induced
osteoblast marker genes Alp 79 and Ocn

73

, so Dlx5 appears to possess a duality

of roles during osteoblast differentiation, both as a direct regulator of Runx2
transcription, as well as a cooperative transcription factor at Runx2 target genes.
Molecular signaling and the vertebrate skeleton – The Wnt pathway
Wnts are secreted, lipid-modified glycoproteins that activate cell surface
receptor-mediated signal transduction pathways to regulate a variety of cellular
activities, including cell fate determination, proliferation, migration, polarity,
and gene expression 80 . In canonical, β-catenin-dependent WNT signaling, a Wnt
ligand binds to binds to a Frizzled receptor and their co-receptors low-density
lipoprotein receptor-related protein 5 (LRP5) or LRP6 to stabilize cytosolic βcatenin via inhibition of a ubiquitinating complex. β-catenin then enters the
nucleus and stimulates the transcription of WNT target genes by interacting
10

with lymphoid enhancer-binding factor 1 (LEF1), T cell factor 1 (TCF1), TCF3 or
TCF4. Non-canonical Wnt pathways not utilizing β-catenin include the
noncanonical planar cell polarity, which also does not employ LRP5 or LRP6,
and noncanonical Wnt/calcium pathway, which requires modulation of
intracellular calcium ion levels. These pathways are further separated by their
choice of ligand; canonical Wnt signaling uses WNT1, WNT3a, WNT8 or
WNT10b, while noncanonical signaling relies on WNT4, WNT5a or WNT11.
Recognition of the Wnt pathway’s involvement in bone biology began with
a punctuation of discovery: in a single year, mutations causing severe alterations
in bone density were identified in four groups of patients with bone mass
disorders, pointing to the canonical branch of WNT signaling. Two of these
mutations were detected in the LRP5 coreceptor necessary for Wnt signal
propagation. Loss of function mutations in LRP5 cause the autosomal recessive
disorder osteoporosis-pseudoglioma syndrome (OMIM# 259770)

81

. Affected

individuals have very low bone mass and are prone to developing fractures and
deformation, though they lack any identifiable defects in collagen synthesis,
anabolic and catabolic hormones, calcium homeostasis, endochondral growth, or
bone turnover. A knockout mouse model confirmed the genotype-phenotype
relationship, and provided insight into the bone mass deficit. Lrp5-/- mice have
low bone mass compared to their wild type littermates, though this feature was
only detectable postnatally 82 . Intriguingly, no aberrations in Runx2 expression
were detected in these mice.
11

The importance of the Wnt pathway in mediation of postnatal bone mass
was further highlighted by the identification of gain of function mutations in
LRP5 (G171V), causing an autosomal dominant high bone mass phenotype 83, 84 .
Molecular investigations recognized the mutation as detrimental for the affinity
of the protein for the extracellular Wnt signaling antagonists DKK1 85, 86 and
SOST 86, 87 . Sost itself is a locus for mutations affecting bone mass. Premature
termination mutations in Sost 88 cause sclerosteosis (OMIM #605740) whereas a
52 kb homozygous deletion downstream of the SOST gene is associated with van
Buchem disease 89 both of whom are characterized by bone overgrowth.
Genetic analysis in the decade following these initial discoveries detailed
the importance of many additional canonical Wnt components (β-catenin, Gsk3ß, Axin2, and Dkk1; reviewed in 90 ) in both osteoblast differentiation and
postnatal bone mass density maintenance. Conditional deletion of -catenin
forces a chondrocytic fate on skeletal precursor cells 91, 92 , a fate suppressed in
these progenitors in response to ectopic activation of Wnt signaling 91, 93, 94 .
However, finer dissection of this process reveals the stage of differentiation as a
strong determinant of the response of a differentiating osteoblast to Wnt
signaling. β-catenin stabilization in MSCs promotes proliferation at the expense
of osteoblastic differentiation, while committed osteoblasts respond to the same
stimulus by accelerating both growth and differentiation, at the expense of
failure of terminal differentiation into mature osteoblasts. One possibility
responsible for this state dependent response is the complex relationship
12

between Wnt signaling and the master regulatory transcription factors Runx2
and sp7. While the Runx2 P1 promoter possesses a Wnt responsive element that
recruits β-catenin and TCF/LEF transcription factors 95 , cells lacking β-catenin,
are, like Lrp5-/- mice, still capable of expressing Runx2 in cells surrounding
developing bone tissue. This suggests that other inputs in the Runx2 regulatory
apparatus are sufficient to induce the primary osteoblast differentiation genetic
program in the absence of Wnt.
Consistent with their effects on mature bone, the regulatory relationship
between sp7 and the Wnt pathway appears to be reciprocal. While canonical Wnt
signaling promotes both osteoblast differentiation and proliferation, sp7
promotes differentiation of maturing osteoblasts, while inhibiting their
proliferative potential. It appears that this is accomplished at least partially by
an sp7-mediated inhibition of Wnt activity. Sp7 appears to control the
expression of the extracellular Wnt antagonist Dkk1 by direct binding to its
promoter, and its expression is indeed abolished in sp7-null embryonic calvarial
cells. Sp7 also inhibits -catenin mediated transcription by direct interaction
with the transcription factor TCF1. Therefore, it has been speculated that
repeated downregulation of Wnt signaling is essential for balancing proliferative
and cell fate priorities during osteoblastogenesis 96 .
Molecular signaling and the vertebrate skeleton – The FGF pathway
Fibroblast growth factors (FGFs) are a family (22 members in both mouse
and human) 97 of secreted growth factors with roles in diverse biological
13

processes that exert signaling activity by binding to tyrosine kinase fibroblast
growth factor receptors (FGFRs), inducing intracellular pathways such as p38
MAPK, PLC, ERK1/2 or PI3K/AKT. Current thinking places the FGF signaling
axis as a positive regulator of proliferation of progenitor cell populations and
growth plate maturation during bone development 98 . In cell culture, FGF
signaling increases proliferation of immature osteoblasts while simultaneously
blocking differentiation 99, 100 .
The identities of and roles of specific Fgf ligands at discrete stages of
skeletal development are poorly understood. Fgf9 is expressed in early
mesenchyme condensations prior to ossification, while Fgf2, Fgf5, Fgf6, and Fgf7
are expressed in the mesenchyme surrounding the ossification. All Fgfs have
been identified in the coronal suture of E17.5 embryos, save for Fgf3 and Fgf4.
While in vitro evidence has shown the capacity for Fgf ligands to stimulate
osteoblast differentiation and or marker genes 101 , animal models have failed to
provide striking evidence of the necessity of a given ligand for a skeletal process,
though it is clear that excessive ligand disrupts proper development. The
construction of an Fgf2 knockout mouse provided an early illustration of this
concept. Fgf2-/- mice are normal in apperance, but have lower bone mass density,
concomitant with decrease thymidine incorporation in calvarial osteoblasts,
suggesting an early proliferation defect behind the adult phenotype 102 .
Consistent with these observations, overexpression of Fgf2 in mice results in
premature mineralization, achondroplasisa and shortening of the long bone 103
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Similar observations were made in experments using Fgf9 knockout and
transgenic mice 104, 105 .
As is not the case for the FGF ligands, there exists much human genetic
evidence regarding the necessity of the FGFR genes in skeletal development. Of
the four FGFRs, FGFRs1-3 are expressed in calvaria mesenchyme. Gain of
function missense mutations in FGFR1, FGFR2, and FGFR3 cause a spectrum of
fourteen disorders, most of whom share a craniosynotosis or chondrodysplasia
feature 106 . Despite the diversity in phenotypes resulting from those mutations,
then, it makes sense to try to understand the common biology in these in these
conditions. Craniosynotosis and chondrodysplasia differ fundamentally in the
physiological process disrupted in their pathology. Craniosynostosis is a failure
of the flat bones of the craniofactial skeleton to delay differentiation in
progenitor cell populations, resulting in premature fusion of the sutures.
However, chondrodysplasia is a defect in endochrondral ossification, often
resulting in shortening of the long bones of the limbs and the axial skeleton in
general. So despite affecting two distinct pathways to mature bone, upregulation
of FGF signaling in developing skeletal tissue results in a common cell biology
defect: premature differentiation of progenitor cells.
Genetic origins of the vertebrate skeleton – Signaling crosstalk
While understanding the functions of individual signaling pathways in
bone development is a necessary effort towards a complete theory of
skeletogenesis, these deconstructions, in isolation, lead to an impoverished view
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of a highly integrated process. Therefore, it is necessary to consider how these
pathways interact, either to enhance or police each other’s activities. Therefore, I
will discuss known connections of each of the systems discussed above.
Signaling crosstalk in the vertebrate skeleton - BMP and Wnt pathways
Studies investigating interactions between Wnt and BMP in osteoblast
differentiation have identified both synergistic and epistatic relationships
between components of these pathways. At a fundamental level, BMP-2 driven
osteogenesis is dependent on the presence of -catenin

107

. Many examples exist

of synergistic activation of osteoblast marker genes by costimulation with BMP
and Wnt ligands at early stages of osteoblastogenesis 107-109 . Several possible
explanations involving intracellular mediators of these signals have been
proposed. In Xenopus embryos and cos-7 cells, Wnt signaling extends the
duration of a ‘pulse’ of BMP signaling by regulating SMAD1 activity via GSK-3
dependent phosphorylation 110 . Other researchers have described a mechanism
involving the physical interaction of SMAD4 with TCF4 and the general coactivator protein p300 111 .
However, at later stages in bone biology, they may have distinctly
antagonistic roles. Where continued Wnt signaling is crucial for maintaining
sufficent levels of bone mass density, BMP signaling at this stage actually acts in
an catabolic manner. Deletion of Noggin, which codes for an extracellular
inhibitor of BMP ligands, led to decreased bone mineral density (BMD) and bone
formation in mice 112 . The extracellular Wnt inhibitors Dkk1 and Sost are
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downstream of BMP signaling 113 , and through their upregulation, Wnt signaling
is attenuated. Genetic evidence for this interaction was observed in an
osteoblast-specific Bmpr1a knockout mouse, which had a high bone mass
phenotype concomitant with upregulated Wnt signaling 113 . BMP inhibition of
Wnt occurs in uncommitted bone marrow cells via sequestration of the GSK-3
inhibitor/Wnt activator DSH by SMAD1 114 .
Another level of BMP and Wnt integration to discuss is the combined cis
regulation of both component and target genes. Chip-seq data from erythoid cells
indicate that many active enhancers in these cells recruit both SMAD1 and
TCF7L2 115 . The promoters of Dlx5 and Msx2, which are routinely and
essentially upregulated in response to BMP signaling, respond synergistically to
BMP and Wnt activation. Unsurprisingly, SMAD1, TCF4 and -catenin are
recruited to these promoters following dual stimulation of these pathways 108 .
Signaling crosstalk in the vertebrate skeleton - BMP and FGF pathways
Unlike the complicated relationship between BMP and Wnt signaling, the
association between BMP and FGF signaling has been described as largely
cooperative. Similarly to its relationship with Wnt, many examples exist where
BMP signaling is in part dependent on the presence of active FGF signaling to
achieve full osteogenic effect. Mice null for Fgf2 have decreased Bmp2 expression
116

, while FGF-2 and FGF-9 increase expression of Bmp2 in calvarial osteoblasts.

Additionally, these ligands inhibit the expression of noggin, an extracellular
BMP inhibitor normally upregulated in response to BMP signaling 117 . FGF
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mediated suppression of noggin is also observed in vivo in the coronal dura
mater during suture development. Noggin maintains the patency of flat bone
sutures in the skull, so it is possible that some of the craniosynostosis phenotype
arising from gain of function FGFR mutations is due, in part, to coordinately
misregulated BMP signaling 116, 118 . FGF also upregulates BMP signaling beyond
the context of increasing ligand-receptor association; Fgf2-/- osteoblasts have
impaired colocalization of phosphorylated SMADs and RUNX2 in response to
BMP-2 signaling, though the reason for this deficit is unclear 116, 119 . Finally,
FGF-2 and BMP-2 have a synergistic effect on fracture healing: FGF-2 has a
critical function at early stage while BMP-2 promotes mineralization at later
stage 120 .
Signaling crosstalk in the vertebrate skeleton – Wnt and FGF pathways
Wnt and FGF signaling have opposing effects during osteoblast
differentiation 121 . The convergence of Wnt and FGF signaling in skeletogenesis
occurs primarily by the suppression of Wnt signaling by FGF signaling. Multiple
mechanisms have been described underlying this process. At a fundamental
level, the expression of components of the canonical Wnt pathway requires FGF
signaling. mRNA expression of Wnt10b, Lrp6, and -catenin are significantly
downregulated in bone marrow stromal cells from Fgf2-/- mice 122 . Exogenous
application of Fgf2 ligand to these cells rescues both the osteogenesis defects
while increasing -catenin stabilization and nuclear localization. Comparative
microarray analysis of osteoblasts derived from patients with gain of function
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FGFR2 mutations identified the transcription factor SOX2 as dramatically (15 to
121 fold) upregulated compared to wildtype cells 99 . Coimmunoprecipitation
experiments demonstrated that SOX2 associates with -catenin in osteoblasts
and can repress activity of a reporter plasmid drive by TCF/LEF binding sites.
Wnt and FGF signaling interactions have also been studied genetically in
the context of skull suture formation. Tellingly, deletion of the gene encoding the
Wnt negative regulator, Axin2, resulted in a phenotype similar to that observed
in craniosynostosis in FGFR gain of function mutations 123 . Upregulation of Wnt
signaling in Axin2-deficient mice was confirmed by increased nuclear
accumulation of -catenin. In concert, the proportion of FGFR positive cells at
the suture was significantly reduced 124 . Further altering the FGF/WNT balance
by generating Axin2-/-, Fgfr1+/- mice produce sutures with ectopic cartilage
formation 125 . Cells at the front of these sutures had upregulated BMP signalling,
as evidenced by increased SMAD phosphorylation. A complex mechanism in
suture mesenchyme has been proposed, where Wnt signaling expands the
population of skeletal precusors, while stimulating BMP signaling to counteract
FGF signaling. In the presence of relatively high levels of FGF signaling, BMP
signaling promoters osteoblastogenesis in the microenvironment, while reduced
FGF signaling results in the effect of BMP to signaling to promote a chondrocytic
fate.

Zebrafish as a model to study vertebrate skeletogenesis
19

Zebrafish enjoy a burgeoning status as a more tractable alternative to the
standard skeletal biology models of mouse and chick126. Development of both the
craniofacial127 and axial128 skeletons has been well characterized. Zebrafish
produce the same skeletal cell types as higher vertebrates, albeit in simpler
patterns129. Additionally, gene expression events in skeletal elements are
orthologous to those observed in higher vertebrates130. Specifically for the
purposes of this work, both zebrafish runx2 orthologs, runx2a and runx2b are
expressed in nascent skeletal elements131. Moreover, the appearance of the
zebrafish skeleton is rapid; the first bony structure, the cleithrumd, is visible
within 72 HPF132, though expression of bone marker genes in the anlagen begins
at approximately 36 HPF133. Potential bone specific deficiencies of the system,
such as the lack of osteocytes or hematopoietic activity in the bone marrow, are
not hindrances for exploring early development134.

Study aims
Despite the identification of skeletogenesis specific roles of the signaling
pathways discussed above and otherse, a coherent narrative of the genetics and
cell biology underlying this process still eludes the field. Because of its singular

d

Most of the imaging in this document will focus on two bones as proxies for the
expression in the rest of the skeleton. The cleithrum is a bone of mesodermal origin, and
is roughly analogous to the shoulder girdle in mammals. Conversely, the opercle is
derived from neural crest, and adopts a fan shaped morphology to lend structural
support to the gill flap.
e These include Notch, Indian Hedgehog, calcineurin, retinoic acid, p38 MAPK, among
others.
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role in both marking and initiating early stages of osteoblastogenesis,
understanding the regulation of Runx2 itself is a potentially fruitful approach to
understanding the biology of this process. Therefore, the rest of this document
will be committed to describing the cis regulatory architecture responsible for
regulating both the presence of the RUNX2 transcription factor itself in putative
skeletal cells, but also the modulation of gene dosage that is so critical for proper
execution of this process. Chapter 2 describes the results of a conservation based
screen for conserved non-coding elements associated with the human RUNX2
locus capable of directing expression to bone. Chapter 3 relates a series of
functional studies on individual elements, identifying upstream regulators with
previously confirmed roles in skeletogenesis. Finally, Chapter 4 integrates the
results from Chapters 2 & 3 for a summary, discussion of the implications of the
work, and suggestions for future avenues of experimental inquiry informed by
this effort.
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CHAPTER 2

A SCREEN FOR RUNX2 ASSOCIATED
ENHANCERS IDENTIFIES THREE CONSERVED
NON-CODING ELEMENTS CAPABLE OF
DIRECTING EXPRESSION TO OSTEOBLASTS IN
VIVO.
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CHAPTER 2
Introduction
The gene encoding the transcription factor RUNX2 was identified as the
underlying cause of the human skeletal syndrome cleidocranial dysplasia (CCD)
24, 126

, resulting from haploinsufficiency. RUNX2 regulates expression of

downstream genes important for osteoblast function, and its forced expression
can upregulate those target genes 25 . Mutation of the mouse gene demonstrated
the requirement for Runx2 in bone formation throughout the skeleton, and its
continued expression is also required for normal bone homeostasis 22, 127 .
The years since its identification have yielded a detailed understanding of the
pathway downstream of Runx2 leading to differentiated osteoblasts, with
identification of many genes whose transcription is directly regulated by Runx2.
Comparatively, almost nothing is known about the transcriptional regulation of
Runx2 itself. This is a critical question, since initiation of Runx2 expression in
development determines when and where bones will form, and its ongoing
expression is important for proper maintenance of bone throughout life.
Numerous signaling pathways have been implicated in its induction, but none
has been shown to directly regulate Runx2 transcription in vivo 128 .
Direct regulation of a gene is accomplished by the binding of diffusible trans
regulatory factors, either directly or to other trans factors, to cis-regulatory
elements (CREs) 129 . CREs are regions of genomic DNA with some role in
activating, maintaining, or repressing transcription of an mRNA product.
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Elements containing or immediately adjacent to the one of the transcriptional
start sites of a gene are generally classified as promoters. They mark the site of
recruitment of RNA polymerase and melting of the DNA strand and
consequently possess an innate directionality. Conversely, enhancers can
positively regulate gene transcription without regard to DNA strand orientation,
and may be located at either a great distance from the transcriptional start site
or, potentially on other chromosomes altogether 130, 131 , though this is not known
to be a common phenomenon in vertebrate genomes. Additionally, exons of
neighboring genes can also function as enhancers 132, 133 . Other forms of cis
regulatory elements include locus control regions and silencers, capable of
preventing gene activation and insulators, which form boundaries to prevent the
spread of a repressive heterochromeric chromatin environment through the
association of the CTCF protein.
Runx2 is somewhat noteworthy in that it possesses two distinct
promoters. The proximal P2 promoter regulates the type I isoform, while the
distal P1 promoter (Runx2 P1) regulates the type II isoform. The two proteins
share the same functional domains and are similarly capable of transactivating
target genes 134 . The P2 promoter is active at a basal level in a broad number of
cells and tissues, including the thymus, cartilage, periosteum, and suture tissue
of the calvarium 135-137 whereas the P1 promoter is active in hypertrophic
chondrocytes and mature osteoblasts 25, 138 . Although in vivo, transcription from
both promoters are necessary for fine-tuning Runx2 expression 139 , they are
24

incapable of directing proper expression of a reporter transgene by themselves 140,
141

, indicating the existence and necessity of a more elaborate cis regulatory

architecture. Also, while most characterized CCD mutations affect the RUNX2
coding sequence, some cases have been associated with translocations of distal
regions 142, 143 or have no identified coding sequence 66 mutations, suggesting the
presence of critical regulatory sequences whose mutation or disruption severely
impairs gene expression.
Therefore, I hypothesized that there must exist additional enhancer elements
necessary to direct Runx2 expression 144 . Methodologies for identifying functional
CREs are an area of ongoing inquiry in the literature, each possessing relative
strengths and inherent limitations. In a developmental context, the current
‘gold standard’ experiment for confirming regulatory potential of a DNA region is
the deletion of that element in the germline or a relevant integrated BAC in vivo
and confirmation of a phenotypic of transgene expression change. The chief
advantage of the approach is the opportunity to observe an element in its native
regulatory environment in a variety of tissue types. Unfortunately, isolating
individual elements using germline modifications in mice is costly and time
consuming. Additionally, functional redundancy between elements may mask or
buffer the consequences of element loss.
Other methods rely on the flood of bioinformatic data that has been made
available as the result of numerous genome sequencing projects as well as
massively parallel sequencing technologies 145 . Current estimates place
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approximately 5% of the human genome under negative purifying selection 146, 147 ,
where evolutionary forces conserve sequence against the caprice of mutation.
However, only 1.5% of the genome appears to have exonic coding potential. The
difference between these proportions—popularly referred to as the ‘dark matter’
of the genome—is due to the relative difficulty of annotating aspects of genes
without protein coding potential. Conservation based methods assume conserved
non-coding elements possess functional importance whose ablation or alteration
would have fitness consequences. While conservation is a generally reliable and
accepted criterion for identifying candidate CREs associated with a given gene,
there has not yet been an agreement in the field regarding the algorithm or
parameters that are best suited for identifying CREs amongst diverse biological
contexts 129 . Notably, deletion of many ‘ultraconserved’ elements in mice resulted
in no observable phenotype 148 . Additionally, while conservation might be a good
approach to discern sites of input for relatively ancient signaling connections, it
is less useful at identifying newly arisen CREs, which are likely to be of the
greatest interest from a evolutionary perspective.
Marrying chromatin immunoprecipitation with genome wide interrogation
techniques such as microarrays and next generation sequencing permits the
mapping of locations of both known transcription factors as well as histone
modifications associated with regulatory activity to the genome in a variety of
cell types and environmental situations. In particular, enrichment of
methylation of 4th lysine of the N-terminus of the histone H3 has been repeatedly
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shown to be a powerful technique for locating promoters (H3K4me3) and
enhancers (H3K4me1/2) in the absence of detectable sequence conservation 149, 150
. However, these approaches are generally poorly suited for study of enhancers
involved in development, because of cell number requirements of precious
embryonic materials as well as their necessarily static nature.
With these experimental approaches and limitations in mind, I decided rely
on moderate conservation amongst vertebrates to identify CREs associated with
the human RUNX2 locus. A list of candidate CREs was generated by
interrogating the locus using PhastCons 151 , an algorithm which relies on
multiple vertebrate genomes to both identify conserved elements, as well as a
quantitative measure of the evidence of that conservation, permitting a ranking
and prioritization of element testing. Because location is a poor predictor of
regulatory function, and enhancers can exist at great distances from their
associated genes, I examined sequences in an interval of >1 Mb containing
human RUNX2.
Finally, the qualities of the systems used to actually confirm regulatory
activity merits discussion. Especially in developmental contexts, in vivo systems
are preferable to cell based assays because of the ability to simultaneously
observe the full range of likely dynamic regulatory activity in all tissues.
Traditionally, mice have been used for this purpose, but for the reasons
discussed above, these are a difficult choice for studying embryonic expression,
as it requires sacrificing a transgenic animal at each time point of interest.
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Additionally, because many transgenes show position dependent effects resulting
in ectopic activation in cells that do not actually reflect biological reality, it is
necessary to examine a number of embryos to ensure that uniform and robust
pattern of expression can be elucidated. In contrast, zebrafish produce hundreds
of optically accessible embryos in single clutch. Finally, a highly efficient
transgenesis methodology based on the Tol2 transposase permits the
construction of potentially hundreds of mosaic transgenic fish in a single
morning 152 .
Specifically to skeletal biology, zebrafish are increasingly being employed as an
alternative to the standard models of mouse and chick 153 . In addition to the
reasons of tractability listed above, they produce the same skeletal cell types as
higher vertebrates, albeit in simpler patterns. The appearance of the zebrafish
skeleton is rapid; the first bone, the cleithrumf, is visible within 72 HPF 154 ,
though expression of bone marker genes in the anlagen begins at approximately
36 HPF 155 . Potential bone specific deficiencies of the system, such as the lack of
osteocytes or hematopoietic activity in the bone marrow, are not hindrances for
exploring early development 156 .
In this chapter, I describe a screen for RUNX2-associated CREs in the human
genome. Candidates were selected on the basis of moderate conservation

f

Most of the imaging in this document will focus on two bones as proxies for the
expression in the rest of the skeleton. The cleithrum is a bone of mesodermal origin, and
is roughly analogous to the shoulder girdle in mammals. Conversely, the opercle is
derived from neural crest, and adopts a fan shaped morphology to lend structural
support to the gill flap.
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amongst vertebrates and tested for in vivo activity in a zebrafish system.
Commonalities and differences in expression domains are also noted.
Materials and Methods
Ethics statement. All animal work was conducted according to national and
international guidelines, and with the knowledge and approval of the
Institutional Animal Care and Use Committee of the University of Pennsylvania.
Identification of conserved non-coding elements associated with RUNX2. To
identify sequences for in vivo analysis, the candidate locus (hg18; chr6:
44904448-45974166) was interrogated for conserved non-coding elements, as
defined by the PhastCons Vertebrate Conserved Elements track during January,
2010 151 . Elements overlapping known RefSeq exons were excluded from further
analysis. The top 50 scoring elements (LOD >454) were amplified by PCR (Table
1) from human genomic DNA with LA Taq polymerase (Takara), and cloned into
the Tol2 transposon containing vector pattP-Tol2-EGFP as previously described
152

.
Transgenesis and expression analyses. Fish were cared for following standard

protocols. Each construct for analysis was injected as previously described in at
least two separate experiments, and mosaic expression of eGFP analyzed in a
minimum of 150 embryos 157 . Embryos were screened from 1- 5 DPF using a
Zeiss V12 Stereomicroscope, and imaged with AxioVision 4.5 software. For those
constructs regulating a consistent expression pattern, embryos were raised to
adulthood and their progeny examined for expression after germline
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transmission. All constructs were examined in at least three independent
transgenic lines for consistent expression. The +210RUNX2:mCherry construct
was made in a version of the same vector with mCherry coding sequence instead
of eGFP. sp7:mCherry fish were made by injection of a modified BAC containing
medaka sp7 regulatory sequences, a kind gift from Christoph Winkler 158 .
Confocal imaging. Embryos were anesthetized in Tricaine and mounted in
MatTek glass bottom culture dishes in 1% low melt SeaPlaque agarose. Images
were acquired on an Olympus IX 81 microscope equipped with a Yokogawa CSU
10 scan head combined with a Hamamatsu EMCCD camera (model C9100-13,
Bridgewater, NJ). Hardware was controlled by Slidebook version 5.0 (Intelligent
Imaging Innovations). Diode lasers for excitation (488 nm for eGFP and 561 nm
for mCherry) were housed in a Spectral Applied Research launch (Richmond
Hill, Ontario). Confocal image stacks were processed with ImageJ
(http://rsbweb.nih.gov/ij).
In situ hybridizations. Whole mount in situ hybridizations were performed as
described 159 , with the following modifications: 0.05% CHAPS detergent was
added to the pre-hybridization and hybridization solutions to prevent embryo
clumping, and the concentration of NBT was reduced 10-fold in the staining
solution to permit overnight development with low background. Stained embryos
were dehydrated by successive methanol washes, cleared in methyl salicylate,
and mounted in Permount medium (Fisher; SP15-100) between bridged
coverslips. Microscopy was performed on an Olympus BX51 with Nomarski
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optics. Images were acquired using Spot Basic version 4.6 (Diagnostic
Instruments). Further adjustments to white balance and contrast were
performed with Adobe Photoshop.
Quantitative PCR. RNA was extracted from whole zebrafish embryos as
previously described 160 . cDNA was synthesized using the cDNA high capacity
transcription kit (Invitrogen). qPCR was performed in 20 µl reactions using ABI
Sybr Green Master mix, and 250M primer concentration. Samples were
amplified using an ABI StepOnePlus real time PCR system.
Identification of cis regulatory elements associated with the zebrafish
orthologs runx2a and runx2b. The program WPH finder was downloaded from
http://rana.lbl.gov/downloads/wph.tar.gz. The three characterized human
enhancers (-460RUNX2, +210RUNX2 and +542RUNX2) were used as substrates
to build word profiles based on the occurrence of 8-mers. These were individually
used scan the loci containing the zebrafish Runx2 orthologs runx2a (chr17:
5385672-5740215;Zv8) and runx2b (chr20: 44206838-44359224;Zv8) using 250
base pair windows offset by 100 base pairs. Repetitive sequences were removed
with RepeatMasker prior to scanning. An arbitrary cut off of Z>5 determined
which candidate elements to progress to functional testing.
Results
A screen for RUNX2 associated enhancers identifies three conserved non-coding
elements capable of directing expression to osteoblasts in vivo.
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As potential cis–regulatory elements for RUNX2, we selected the 50 most
conserved non–coding sequences within the ~1Mb interval bounded by the 3'
UTR of the overlapping gene SUPT3H and the 3' UTR of the downstream gene
CLIC5 in the human genome(Figure 1). We grouped proximate sequences into
larger amplicons, resulting in 36 constructs (Table 1). Each sequence was tested
for in vivo enhancer activity, through its ability to direct tissue–specific eGFP
expression in zebrafish. We initially screened by examining approximately 150
mosaic injected embryos for fluorescence from 1-6 days post fertilization (DPF);
constructs positive in the initial screen were passed through the germline for
detailed characterization.
In total, I identified three enhancers capable of directing reporter gene
expression to osteoblasts: a distant upstream enhancer located in the last intron
of SUPT3 (-460RUNX2)g, a downstream enhancer in the intergenic space
between RUNX2 and CLIC5 (+542RUNX2), and one in the last intron of RUNX2
itself (+210RUNX2).
Comparison of transgene activity by confocal microscopy and in situ
hybridization reveals distinct, yet redundant expression patterns.
While all three enhancers direct expression to osteoblasts, they do not have
identical activities. Prior to formation of the first bones, +210RUNX2 is
transiently active in the branchial arches, as evidenced by GFP expression in

The nomenclature used here and subsequently in this document to identify specific
enhancer elements is the distance from the transcriptional start site of a gene in
kilobases, relative to the directionality of the open reading frame.
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live embryos at 2DPF(Figure 2.2j). An earlier and less enduring expression in
the branchial arches is directed by +542RUNX2 between 24-48 HPF (data not
shown). +542RUNX2:eGFP expression is first detectable in the cleithrum
anlagen between 28-32 HPF, while this activity is relatively delayed in embryos
carrying the other two transgenes (Figure 2.3a,d). Referring to the confocal data
at 3DPF shows that, again, while all three transgenes drive expression in
cleithrum in osteoblasts, the expression is much more pronounced in the
+542RUNX2:eGFP (Figure 2.2f) and -460RUNX2:eGFP lines (Figure 2.2o).
Furthermore, +542RUNX2 mediated expression in the cleithrum at this stage is
uniform along the dorsal ventral gradient, while in -460RUNX2, expression is
relatively punctuated at the dorsal and ventral extremes of the bone.
All three enhancers are active in cells of the opercle (Figure 2.4), a neural–
crest derived bone 161 that forms by membranous ossification lateral to the
branchial arches. However, +210RUNX2 directs expression to the
osteoprogenitors surrounding the edges of the bone (Figure 2.4j,m,p), while the
activity of the other two enhancers is confined to cells within the bone itself.
Similarly to the expression differences observed in the cleithrum, +542RUNX2
directs expression uniformly throughout the bone (Figure 2.4s,v,y), while
+460RUNX2 expression is enhanced in the strut and fan structures of the
opercle (Figure 2.4 a,d,g)
+154runx2a, the zebrafish ortholog of +210RUNX2, is conserved at the levels of
sequence and function.
33

While identifying conserved enhancers between distantly related species is
not always a straightforward effort, alignment of vertebrate genomes using
MultiZ 162 in the UCSC genome browser revealed apparent linear alignment
delement, +154runx2a, directs expression the branchial arches at 3DPF (Figure
2.5 a) as well as to bony elements such as the opercle and branchiostegal rays at
5DPF (Figure 2.5 b,e).
Only +542RUNX2 directs expression to the developing vertebrae.
Later in zebrafish development (10-21 DPF), the vertebrae form from
migrating sclerotome cells that surround the spinal cord 163 . Though at 5DPF, all
three enhancers direct expression to all visible skeletal structures, the ability to
direct expression to the vertebral arches at 14DPF is limited to +542RUNX2
(Figure 2.6c). Some expression by -460RUNX2:eGFP is visible in the centra of
the vertebrae. (Figure 2.6a). +210RUNX2 failed to direct expression to any
aspect of the vertebral column (Figure2.6b).
Chromatin features of identified enhancers.
As discussed in the introduction, enhancer associated chromatin marks are
an often-employed method to identify loci with regulatory activity in a cell or
tissue type being studied. There exists an unpublished, publicly available ChIPSeq data set from a normal human osteoblast cell line as part of the ENCODE
projecth. Enrichment for regulatory element associated marks (H3K4me1,

According the documentation accompanying the data set, the cell line is normal
human osteoblasts (NHOst) from Lonza (#CC-2538). The ChIP-Seq data was
produced by a collaboration of Bradley Bernstein and Greg Crawford.
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H3K4me2, H3K27Ac) was examined as well as recruitment of the enhancer
associated coactivator p300 (Figure 2.7). +542RUNX2 and +210RUNX2 were
significantly enriched for p300, as well as H3K4me1 and H3K4me2, and were
identified as peaks in the data set as determined by a hidden Markov model
algorithm. Curiously, no enrichment for any of the studied histone modifications
or proteins was observed in -460RUNX2.
The three RUNX2-associated enhancers contain enough information content to
efficiently identify other skeletal specific enhancers in a non-conservation based
approach.
With the limitations of conservation based approaches to discovering
CREs in mind, I wanted to explore whether other methodologies might be
efficient at identifying enhancers associated with the zebrafish RUNX2
orthologs, runx2a and runx2b, for which there are few alignable genomes
available to detect conservation. One such strategy involves utilizing the
information content of known enhancers as a basis for predicted new ones from
untested sequence data. WPH Finder is such an algorithm that has been
successfully used to recognize enhancer elements not identifiable by linear
conservation between Drosophila species 164 . It trains itself by counting the
occurrence of specific eight letter DNA ‘words’ (which likely correspond to
transcription factor binding sites, or other features conferring regulatory activity
upon an element), forming a profile of these word, and then testing windows of
candidate sequences for overrepresentation relative to it.
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Using this methodology, the loci of the zebrafish Runx2 orthologs, runx2a and
runx2b were scored for word profile similarity to the each of the three known
human enhancers (Tables 2.2. 2.3). Eighteen candidates were tested from the
runx2a locus, and ten were examined from that of runx2b. In contrast to the
relatively low rate of skeletal enhancer activity identified in conserved
candidates from the human locus (3/38 = 7.8%), 38.9% (7/18) of amplicons tested
from the runx2ai locus and 50% (4/10) of those from runx2b showed some pattern
of skeletal expression (Figure 2.8a,b). Notably, almost all of the positive elements
(11/12) fall within the coding region of either one of the Runx2 orthologs, or
supt3h, whose syntenic relationship with Runx2 is ancient. Representative views
of expression patterns of these elements show expression in both subsets of
osteoblasts as well as cartilaginous structures (Figure2.8c-h).

i

These numbers exclude +154runx2a, which had already been shown to regulate a
skeletal expression pattern.
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Figure 2.1. – Broad distribution of osteoblast specific enhancers at the
RUNX2 locus. The RUNX2 locus (chr6: 44,904,448-45,971,166, hg18) as
represented in the UCSC Genome Browser is shown, with the conserved non–
coding elements tested for enhancer assay indicated at top. Elements testing
positive for osteoblast expression in vivo are shown in green, while those with no
activity in skeletal tissues are indicated in red. Tracks displaying all conserved
elements as defined by PhastCons amongst vertebrates and mammals are
displayed at the bottom of the figure to visualize relative conservation across the
genomic region.
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Figure 2.2 -- Expression patterns of three human RUNX2 associated
enhancers. Lateral views of doubly transgenic zebrafish embryos for sp7:mCh
and -460 RUNX2:eGFP (A-I), +210RUNX2:eGFP (J-R), and +542RUNX2 (Q-AA)
were imaged at 2DPF and 3DPF. In 2DPF embryos, coexpression of sp7:mCh
and -460RUNX2:eGFP (A) and +542RUNX2 :eGFP (S) in the developing
cleithrum, but not in +210RUNX2 (J). Conversely, branchial arch expression in
+210RUNX2:eGFP is apparent at 2DPF. All three RUNX2 transgenes express in
the opercle anlage at 3DPF with sp7:mCh (D,M,V). Ventral views imaged at
5DPF demonstrate concomitant RUNX2 transgene expression in later
ossifications (G,P,Y).ba, branchial arches; bs, brachiostegal ray; cl, cleithrum; de,
dentary mx, maxilla; op, opercle; Scale bar = 50 mm
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Figure 2.3 -- Differential expression initiation times in the cleithrum
anlagen. Embryos from each transgenic line were fixed at 4 hour intervals and
analyzed by in situ hybridization with an eGFP probe to determine onset of
expressing in the cleithrum. Dorsal views of representative embryos of
+542RUNX2:eGFP (a,d), +210RUNX2:eGFP (b,e) , and +542RUNX2:eGFP (c,f).
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Figure 2.4 – Distinct expression domains in the developing opercle.
Lateral views of the opercle in doubly transgenic zebrafish embryos for sp7:mCh
and (a-i), -460 RUNX2:eGFP (j-r) +210RUNX2:eGFP, and (q-aa) +542RUNX2
were imaged at 3DPF, 4DPF and 5DPF; Scale bar = 10 mm

43

Figure 2.5 – +154runx2a, a conserved ortholog of +210RUNX2, directs
expression to the branchial arches and osteoblasts. Lateral (a-d) and
ventral (e-g) of doubly transgenic zebrafish for +154runx2a:eGFP and
+210RUNX2:mCh at 3DPF(a) and 5DPF (b-g). ba, branchial arches; bsr2,
brachiostegal ray 2 bsr3, brachiostegal ray 3; op, opercle;
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Figure 2.6 -- +542RUNX2 directs expression to the developing vertebral
arches. Lateral views of the developing vertebrate column of doubly transgenic
zebrafish for the indicated RUNX2:eGFP transgene and sp7:mCh at 14 DPF. 460RUNX2:eGFP expression (a) is directed to the anterior edge of the
presumptive vertebrate. +210RUNX2:eGFP (b) does not express in any portion of
the anatomy and +542RUNX2:eGFP (c) directs expression to the vertebral
arches. (d-f) demonstrate sp7:mCh mediated expression; (g-i) shows a merge of
these two pattern,
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Figure 2.7 – Analysis of chromatin environment at three RUNX2
associated enhancers in a normal human osteoblast cell line. The human
skeletal enhancers -460RUNX2 (a), +210RUNX2 (b), +542RUNX2 (c) are shown
as represented in the UCSC genome browser along with tracks indicating both
the enrichment of and presence of peak of the following histone
modification/proteins in normal human osteoblast cell lines as defined by ChIPSeq.
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Figure 2.8 – Screen for skeletal enhancers associated with the zebrafish
Runx2 orthologs, runx2a and runx2b. The runx2a(a; chr17: 53856725740215;Zv8) and runx2b(b; chr20: 44206838-44359224;Zv8) loci(chr6:
44,904,448-45,971,166, hg18) as represented in the UCSC Genome Browser is
shown, with the elements tested for enhancer assay indicated at top. Elements
testing positive for skeletal expression in vivo are shown in green, while those
with no activity in skeletal tissues are indicated in red. Tracks displaying all
conserved elements as defined by 6 way MultiZ alignment displayed at the
bottom of the figure to visualize relative conservation across the genomic region.
Representative images of transgenic fish carrying these elements illustrate the
diversity of skeletal expression observed. -52runx2a:eGFP (c) expresses in a
subset of ossifying structures at 5DPF; +54runx2b:eGFP (d) expression is
exclusive to osteoblasts; +28runx2b:eGFP (e) expression is found in the
cartilaginous elements of the neurocranium; -32runx2a:eGFP (f) expressed in the
branchial arches as well as the dentary and maxilla forming the mouth; and
+38runx2b:eGFP (h) expresses in the pharyngeal skeleton and dermal bones. ba,
branchial arches; bh, basihyal; bs, brachiostegal ray; cb5, ceratobranchial 5; ch,
ceratohyal; chb, ceratohyal bone; cl, cleithrum; de, dentary; e, ethmoid; mk,
Meckel’s cartilage; mx, maxilla; op, opercle; pq, palatoquadrate
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Table 2.1. Sequences at RUNX2 locus tested for enhancer activity. Each
element is named for the distance in kilobases from the transcription start site of
RUNX2; the location of each conserved region is given as coordinates in hg19,
chr6. Where multiple conserved sequences were grouped into one amplicon, the
LOD scores for each are listed separately. The primer sequences are those used
to amplify the elements from genomic DNA for testing. The three elements in
bold are those with activity in osteoblasts.
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Produc
Coordinates(Zv8
Name

)

+321runx2

chr17:5,278,105-

a

5,278,353

+261runx2

chr17:5,338,455-

a

5,338,703

+258runx2

chr17:5,341,255-

a

5,341,503

+229runx2

chr17:5,371,055-

a

5,371,303

t size

Simil

(bp)

arity

F primer

R primer

ACAGATGGCGGTGAAGCAGT

GCACGTCCGAATGTCAACAA

1061

-460

TGTGAAGCTGCTTTGACACAATC

CGGTGTCCTGTTGCTCAGTG

870

+542

CGAGCGTCCATTCACAAACA

AGGAAACACTGAAGGACAAAATGC

852

-460

CCCAACGTCGGCTTACGATA

TTGCAGTGAGATTGCGTTGG

892

+542
-

+206runx2

chr17:5,392,750-

a

5,393,159

+179runx2

chr17:5,420,855-

a

5,421,103

AGCACCACCACCAACTGGAT

460,+
GGAGCAGCTGAAGAGGCTTG

938

210

CTAGCGCCATTGCTGGTTTC

ATCAGATTCCATGCGGTTCG

991

-460

AGCAGTTACGCTTTTGATGGAG

ACATATTTGGCGCTCGCAGT

1017

-460

TCTGCTGGCCCATAAGAAAAA

TCTTGGAGCAACTGGCAAGC

882

-460

chr17:5,529,955+70runx2a

5,530,203
chr17:5,579,405-

+20runx2a

5,579,653
chr17:5,585,655-

+14runx2a

5,585,903

CAAGCAGTGACTGACAAATGAAAT
TTCAATGGACTTTGATTCAGCTT

G

852

+542

CGGCAGTGATGACAAAACCA

TCACCACGACCTGCAGAAGA

895

-460

TCCTAAAGCGGGAGCACAAA

TGACCCCGAAACAGGAGAGA

865

-460

TGTCAGTGGTCCTGCGTTGT

TGACTGAAGGCAGTCGACCA

884

+542

GGCAACCACAAATTGAAAACC

CCGCAACCATACGGGACTAA

1455

+542

CTCCCTTCATGGTGGCTTCA

CCTCAAACCAGGGCACTAAGAC

949

-460

AGCGATAGAGCCGAGACGTG

ACTGAAGCTGCGTCCCAAAA

2456

+542

chr17:5,599,105+1runx2a

5,599,353
chr17:5,600,005-

-1runx2a

5,600,253
chr17:5,600,505-

-2runx2a

5,600,753
chr17:5,632,105-

-32runx2a

5,632,353
chr17:5,651,555-

-52runx2a

5,651,803

-

chr17:5,740,055-

140runx2a

5,740,303
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-

chr17:5,741,305-

CGAACAGACAGATGAATAAAAAGACA

141runx2a

5,741,553

A

GCAACCCATCTCTGGGAAAC

1262

+542

TGGGCTGGAGACCAAGAAAA

TGCATTGCACATAGGGGACA

1192

+210

TCCCGAAGATCTGGCAAATG

GGCCTGGATGCATCATTTTT

863

+460

chr17:5,750,755-150runx2a

5,751,003
chr17:5,753,255-

-153runx2a

5,753,503

Table 2.2. Sequences at the runx2a locus tested for enhancer activity.
Each element is named for the distance in kilobases from the transcription start
site of runx2a. The primer sequences are those used to amplify the elements
from genomic DNA for testing. The seven elements in bold are those with
skeletal activity. Similarity indicates the human RUNX2 associated enhancer to
which WPHFinder identified word profile similarity.
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Name

Coordinates(Zv8)

F primer

R primer

Product size (bp)

TGCGCTCTTTCCAGCAATTT

TGGGCACGCTATGATGTGAC

921

GTGAAGGCTCCGCTCACCT

GGCAAAGACATACCAGGCAAA

993

GCGGGGCATGTCAGATTCTA

CGACAGAGAGGTGAGCGTGA

907

CCAAAACAATGAACGGCAGA

CGGCAGCCAGAAGAGAGAAC

918

ACCATCCGACAAGCTGATCC

TGGAAATCAATGGGGCAAAA

909

TTGAAGCGGGGTTCATTTTG

GCCCGAACATGAAGGTAACTC

940

TGTGCTCACCTTTAAGTGGTTCA

GGGAGAGAGCCCTGAGCATA

884

TGGTTCTTAGATGGCAATGAGC

CCGTCTCGATTCCTTCAATCC

930

GGGAAACATCCATACATAAAAAGTGTT

GAAACACACACTCAATCACACTCA

1000

TGCTTTAATTTATCATCCTTTTGCAG

CCTAACGTGGCGAAAAGGCTA

895

chr20:44,131,047-45runx2b

44,131,967
chr20:44,121,758-

-36runx2b

44,122,750
chr20:44,075,029-

+11runx2b

44,075,935
chr20:44,058,608-

+28runx2b

44,059,525
chr20:44,121,758 -

+38runx2b

44,122,750
chr20:44,034,157-

+52runx2b

44,035,096
chr20:44,032,209-

+54runx2b

44,033,092
chr20:44,025,533-

+61runx2b

44,026,461
chr20:44,019,065-

+66runx2b

44,020,088
chr20:44,002,595-

+84runx2b

44,003,488

Table 2.3. Sequences at the runx2b locus tested for enhancer activity.
Each element is named for the distance in kilobases from the transcription start
site of runx2b. The primer sequences are those used to amplify the elements
from genomic DNA for testing. The five elements in bold are those with skeletal
activity.
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CHAPTER 3

FUNCTIONAL CHARACTERIZATION OF RUNX2
ASSOCIATED ENHANCERS.

55

CHAPTER 3
Introduction
Having identified three RUNX2 associated enhancers from the human
genome capable of directing expression to osteoblasts in Chapter 2, I attempted
to characterize upstream regulators for each CRE. Fortunately, the transgenic
fish lines I created to describe expression patterns also serve as a useful platform
to study the underlying biology of their reporter constructs.
Materials and Methods
Site directed mutagenesis. Predicted, conserved transcription factor binding
sites in +210RUNX2 were identified via linear alignment to its zebrafish
ortholog, +154runx2a, using Clustal W
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Binding sites were individually
mutated via PCR. Briefly, each site was converted into a unique restriction site
via two parallel PCR reactions with primer pairs that introduced the restriction
site and attB sequence flanking each ampliconj. A subsequent digestion and
ligation step produced a mutagenized enhancer competent for Gateway
recombination. For -460RUNX2mutTCF and +542RUNX2mutDLX, the mutated
enhancer sequences were synthesized (GeneWiz), and cloned directly into pattPTol2-egfp as described in Chapter 2.
Drug treatments. To screen for responsiveness to candidate signaling
pathways, embryos transgenic for each enhancer construct were treated from 48

j

Mutagenized +210RUNX2 constructs were constructed by Gina Mahatma.
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to 72 HPF with inhibitors of FGF signaling (SU5402; 10M) BMP signaling
(dorsomorphin; 30M), retinoic acid (DEAB; 50M), notch (DAPT; 20M),
hedgehog (cyclopamine; 50M) and calcineurin (FK506; 3M) signaling and
screened for changes in GFP expression. Additionally, +210RUNX2:egfp embryos
were treated from 28-32 HPF, or +210RUNX2:mCh embryos from 100-104 HPF,
with SU5402 at 10 µM, and -460RUNX2:mCh transgenic embryos were treated
from 52-56 HPF with GSK3 inhibitor XV at 5µM, before being harvested for in
situ hybridization or Q-PCR analysis. For all treatments, drugs were dissolved in
DMSO to make stock solutions, which were diluted into embryo medium;
additional DMSO was added to equalize concentration for all treatments.
Heat shock treatments. Embryos doubly transgenic for -460RUNX2:mCh and
hsp70:dkk1 165 were immersed in pre–warmed embryo medium at 37C for 30
minutes at 52 HPF. Following heat shock, embryos were transferred to fresh
embryo medium at 28.5°C and incubated for 3.5 hours before harvesting for
analysis. For +542RUNX2:egfp, embryos doubly transgenic with either
hsp70:bmp2b 166 or hsp70:chd 167 were similarly heat shocked at 48 HPF, and
harvested at 56 HPF.
DNA sequence alignments. Orthologs of human sequences were identified by
BLAT. Sequences were downloaded from the UCSC genome browser, curated
into FASTA files and aligned using Clustal X (http://www.clustal.org)
Confocal imaging, in situ hybridizations, zebrafish transgenesis and
quantitative RT-PCR all performed as described in Chapter 2.
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Results – Characterization of +210RUNX2
Identification of conserved predicted transcription factor binding sites in
+210RUNX2
The search for sequence features potentially critical for the ability of an
enhancer to direct skeletal expression was facilitated greatly in the example of
+210RUNX2. Unlike -460RUNX2 and +542RUNX2, +210RUNX2 is deeply
conserved, with orthologous sequences alignable from mammals to teleosts (Fig.
3.1). The site of conserved sequences themselves was similarly preserved; all are
located in the final intron of either Runx2 or a putatively orthologous gene in
more poorly annotated genomes. There are several conserved predicted
transcription factor binding sites, including two adjacent inverted binding sites
for Ets-related factors (containing a characteristic 5’-GGA(A/T)-3’ core), a binding
site for proteins containing a POU DNA binding domain, and one for RUNX2
itself.
Functional testing of conserved predicted transcription factor binding sites in
+210RUNX2
In order to test what, if any, function these deeply conserved sequences had
with regard to the function of the enhancer, these potentially critical residues
were individually and specifically ablated in new transgenic constructs (Figure
3.1) Single insert transgenic lines were constructed as in Chapter 2, and these
were crossed onto fish carrying the wild type +210RUNX2 sequence driving the
expression of mCherry (+210RUNX2:mCh). Although only representative
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microscopic photography is demonstrated below, at least three lines of each
transgene have been constructed to confirm the changes in enhancer activity.
The +210RUNX2 RUNX2 binding site mediates bone expression.
Removal of the RUNX2 binding site produced an enhancer that failed to
direct expression to bone at any time during the first five days post fertilization.
(Figure 3.2 a-c). However, this altered enhancer was still capable of directing
early expression to the branchial arches (Figure 3.2d-f).
The +210RUNX2 Ets binding sites mediate branchial arch expression.
Without the conserved Ets binding sites, +210RUNX2 is still competent to
direct expression to bony tissues, though this does appear to be less robust
compared to the activity of the wild type enhancer (Figure 3.3 a-c). Possible
position integration effects on the autonomy of the transgene currently confound
confirming this quantitatively. More strikingly, however, this altered enhancer
failed to direct expression to the branchial arches at 3DPF (Figure 3.3 d-f).
The +210RUNX2 POU binding site has no confirmable effect on transgene
activity.
Eliminating the POU binding site in +210RUNX2 did not compromise its
ability to direct expression to the domains of either the branchial arches or
osteoblasts (Figure 3.4a,d). eGFP expression driven by +210RUNX2mutPOU did
appear to be more intense than that typically driven by the wildtype enhancer,
suggesting that the conserved sequence might actually have a role in
attenuating expression.
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+210RUNX2 directed expression is a direct target of FGF signaling.
Because of the presence and functionality of two inverted Ets binding sites in
+210RUNX2, I sought to understand what signaling pathways might be
mediating gene regulation through those conserved sites. Ets transcription
factors are often found to be downstream of the FGF signaling pathway 168-170 ,
which, in turn, has a well-appreciated role in skeletogenesis and Runx2
regulationk. The small molecule inhibitor SU-5402 is a potent and selective
vascular endothelial growth factor receptor (VEGFR) and fibroblast growth
factor receptor (FGFR) inhibitor 171 . An initial treatment of 10uM from 24-48
HPF reduced +210RUNX2:eGFP mediated fluorescence in the branchial arches
(Fig3.5a,b) To confirm this downregulation was a direct result of modulating
FGF signaling, I treated +210RUNX2:eGFP transgenic embryos with the Fgf
inhibitor SU5402 from 28-32 HPF. In situ hybridization showed specific
reduction of egfp expression in the branchial arches (Fig. 3.5c-f), and Q-PCR
confirmed a quantitative reduction in transcript levels (Fig. 3.5g). While the ETS
binding sites are not absolutely required for the later activity of +210RUNX2 in
differentiated osteoblasts, activity of the enhancer was quantitatively decreased
by pharmacological inhibition of FGF signaling from 100-104 HPF (Fig. 3.5h),
demonstrating continued regulation of enhancer activity by the FGF pathway
during osteoblast differentiation.
Results – Characterization of +542RUNX2

k

Reviewed in Chapter 1
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The -460RUNX2 and +542RUNX2 enhancers are less deeply conserved,
complicating prediction of transcription factor binding sites. To provide evidence
for specific regulatory inputs, I pharmacologically altered activity of candidate
signaling pathways in transgenic embryos. Changes in BMP, FGF, retinoic acid,
notch, hedgehog, calcineurin, and canonical Wnt signaling had no effect on
+542RUNX2 activity (data not shown).
A conserved subelement of +542RUNX2 is sufficient to direct osteoblast
expression.
To better localize the essential components of +542RUNX2, I created
transgenic lines containing the most conserved cores of the element (Figure 3.6a;
Table3.1) driving eGFP expression. The more conserved of the two (MC1;
Phastcons LOD = 773) directed expression to osteoblasts in a similar manner to
the entire element (Figure 3.6b,c). However, bone expression was notably less
robust than that driven by +542RUNX2. +542RUNX2MC2:eGFP (Phastcons =
334) expresses in the basihyal and ceratohyal cartilages (Figure 3.6d,e),
components of the pharyngeal skeleton, but this does not comprise part of the
expression pattern normally dictated by the intact wild type element.
A conserved DLX binding site is necessary for +542RUNX2 activity.
Alignment of the +542RUNX2 enhancer with the orthologous sequence from
chicken revealed several conserved predicted binding sites (Figure 3.7a).
Initially, I hypothesized that SATB2 might be directly regulating +542RUNX2
because of the generalized delay in bone formation observed in Satb2-/- mice 172 .
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However, ablation of this sequence failed to curtail osteoblast expression
directed by the enhancer (Figure 3.7b,c). Subsequently, I mutated the core of the
Dlx binding site and observed no eGFP expression in 500 embryos injected with
the resulting construct, compared to the readily observable mosaic expression
regulated by the wild–type sequence (Figure 3.7d,e). Transgenic embryos from
+542RUNX2mutDLX:eGFP founders showed no eGFP expression, despite
evidence of germline transmission of the transgene (Figure 3.7h) confirming
requirement of the Dlx binding site for enhancer activity.
Results – Characterization of -460RUNX2
A drug screen identifies GSK-3ß as an inhibitor of -460RUNX2 mediated
expression.
Treatment -460RUNX2:egfp fish with a small molecule inhibitor of GSK3 from
48-72 HPF resulted in a broad upregulation of eGFP expression (Figure 3.8a,b).
To confirm that this effect is a direct effect of modulating the Wnt pathway, a
narrower window of treatment from 52-56 HPF (which is relevant to the
initiation of -460RUNX2 mediated expression in the cleithrum; Figure 2.3)
demonstrated a similar pattern of upregulation (Figure 3.8c,d). GSK3 is an
inhibitory component of the canonical Wnt signaling pathway, but can also
function in other signaling pathways. To confirm Wnt regulation of -460RUNX2,
we generated embryos doubly transgenic for -460RUNX2:mCh and the Wnt
inhibitory protein Dkk-1 under control of the hsp70 promoter (hs:Dkk1GFP) 165 .
A brief heat shock substantially reduced expression of mCherry (Figure 3.8e,f).
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-460RUNX2 requires two conserved TCF/LEF binding sites to direct
expression.
Canonically, the endpoint of Wnt mediated signaling is the recruitment of
members of the TCF/LEF family of transcription factors to cognate DNA binding
sites 173 . There are two predicted TCF/Lef1 binding sites in the -460RUNX2
sequence, conserved among mammals (Figure 3.9a,b), so I created a transgene in
which these sites had been mutated (-460RUNX2mutTCF:eGFP). We observed
no eGFP expression in >500 injected embryos (Figure 3.9d). 460RUNX2mutTCFLEF:eGFP founders showed no eGFP expression, despite
evidence of germline transmission of the transgene (Figure 3.9e,f) confirming
requirement of the TCF/LEF binding sites for enhancer activity.
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Figure 3.1 -- Deep linear conservation between +210RUNX2
and other vertebrate orthologs. Alignment to orthologous sequences from
other vertebrates reveals conservation of predicted transcription factor binding
sites, including RUNX2 itself, a binding site for transcription factor containing a
POU domain and a pair of inverted sites for the Ets family of transcription
factors.
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Figure 3.2 – The Runx2 binding site mediates +210RUNX2 directed bone
expression. (a-c) Lateral views of a doubly transgenic
+210RUNX2mutRUNX2:eGFP; +210RUNX2:mCh zebrafish show no expression
in any bony tissue at 5DPF driven by +210RUNX2mutRUNX2, while this
activity is intact in +210RUNX2:mCh. (d-f) Ventral views of a doubly transgenic
+210RUNX2mutRUNX2:eGFP; +210RUNX2:mCh zebrafish show both
transgenes expressing in the branchial arches at 3 DPF. ba, branchial arches;
cb5, ceratobranchial 5; cl, cleithrum; op, opercle
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Figure 3.3 – The ETS binding sites mediates branchial arch expression.
(a-c) Lateral views of a doubly transgenic +210RUNX2mutETS:eGFP;
+210RUNX2:mCh zebrafish show attenuated expression in bony tissue at 5DPF
driven by +210RUNX2mutETS, while this activity is intact in
+210RUNX2:mCh. (d-f) Dorsal views of a doubly transgenic
+210RUNX2mutETS:eGFP; +210RUNX2:mCh zebrafish show failure of
+210RUNX2mutETS, to express in branchial arches at 3DPF, while this activity
is intact in +210RUNX2:mCh. ba, branchial arches; cb5, ceratobranchial 5; cl,
cleithrum; op, opercle
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Figure 3.4 – The POU binding site is not essential for +210RUNX2
activity during embryogenesis. (a-c) Lateral views of a doubly transgenic
+210RUNX2mutPOU:eGFP; +210RUNX2:mCh zebrafish demonstrate
coexpression in bony tissue at 5DPF by both transgenes. (d-f) Dorsal views of a
doubly transgenic +210RUNX2mutPOU:eGFP; +210RUNX2:mCh zebrafish
show coexpression in branchial arches at 3DPF by both transgenes. ba, branchial
arches; cb5, ceratobranchial 5; cl, cleithrum; op, opercle
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Figure 3.5 – +210RUNX2 is regulated by the FGF signaling pathway. a,b)
Treatment of +210RUNX2:egfp transgenics with the FGF inhibitor SU5042 from
24-48 HPF resulted in loss of transgene expression in the branchial arches. c-f)
As show shown by in situ hybridization for egfp, a narrow window of treatment
from 28-32 HPF this loss of expression is specific and direct. g,h) Q-PCR
confirmed a quantitative decrease in reporter gene expression following
treatment for the same interval, and similarly following a later treatment from
100-104 HPF. Views in a and b are lateral, and in c-f, dorsal, with anterior to the
left.
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Figure 3.6 – Subcloning of +542RUNX2 localizes osteoblast activity to a
433 bp fragment. a) Genome browser view of the original +542RUNX2 element
with tracks indicating the location of the amplicons for subcloning (black) and
Phastcon elements upon which those amplicons were designed (brown). b,d)
Lateral views of 5DPF transgenic embryos carrying +542RUNX2MC1:eGFP (b)
or (d) +542RUNX2MC2:eGFP. c,e) Ventral views of 5DPF transgenic embryos
carrying +542RUNX2MC1:eGFP (c) or (e) +542RUNX2MC2:eGFP. ba, branchial
arches; bh, basihyal; bs, brachiostegal ray; ch, ceratohyal; cl, cleithrum; de,
dentary; op, opercle;
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Figure 3.7 – Identification and functional testing of conserved
transcription factor binding sites in +542RUNX2A) Alignment of
+542RUNX2 and +312RUNX2(gg) along with transcription factor binding sites
identified in both by Transfac (blue), Genomatix (orange), or Uniprobe (red) b,c)
Representative views of eGFP expression pattern in
+542RUNX2mutSATB2:eGFP at 5DPF. d) Alignment of a predicted SATB2
binding site to other vertebrate orthologs. Sequence of mutagenized construct is
shown below. e) Following injection of +542RUNX2:egfp, mosaic expression in
bones, including the cleithrum of two different embryos (arrows) is readily
apparent. f) In contrast, >500 embryos injected with +542RUNX2mutDlx:eGFP
showed no mosaic expression. g) Alignment of a predicted Dlx binding site to
other vertebrate orthologs. Sequence of mutagenized construct is shown below.
h) Presence of +542RUNX2mutDLX:eGFP in non-expressing progeny of injected
founder was confirmed by PCR and sequencing of transgene. cb5;
ceratobranchial 5; cl, cleithrum; de, dentary; mx, maxilla; op, opercle.
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Figure 3.8 – -460RUNX2 mediated expression is responsive to Wnt
mediated signaling. Compared to control (a), activity of -460RUNX2 is
increased by treatment from 48-72 HPF with GSK3b inhibitor XV. (b) A
narrower window of treatment (52-56HPF) shows rapid upregulation (d) relative
to control (c). -460RUNX2 mediated expression (e) is abolished by ectopic
expression of the Wnt inhibitor dkk1 by heat shock (f). cl, cleithrum; op, opercle
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mutTCF

a

mutTCF

b
d

+460RUNX2mutTCFLEF:eGFP

f

c

+460RUNX2:eGFP injected

e

Figure 3.9 – -460RUNX2 regulatory competency requires two conserved
TCF/LEF binding sites. a,b) Alignment of vertebrate genomes to conserved
TCF/LEF binding sites (a) at chr6:44,835,639-44,835,645(hg19), and b)
chr6:44,836,005-44,836,012(hg19) in -460RUNX2. Residues that have been
changed in the mutagenized transgene are indicated below the alignment. c)
Following injection of -460RUNX2:eGFP, mosaic expression in bone is readily
apparent at 5 DPF, seen in the cleithra of multiple injected embryos (arrows). d)
In contrast, following injection of -460RUNX2mutTCFLEF:eGFP, no expression
was seen in >500 embryos. PCR and sequencing of progeny from injected fish
confirmed the presence of the transgene with ablated TCF/LEF binding sites (f),
compared to sequencing of the transgenics with wildtype sequence (e).
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Size
Name

F primer

R primer

+542RUNX2
MC 1

(bp)

chr6:45,945,982AGACAACACGGGCTCATCGT

CCCCAAGGGTCTCTGGATTT

+542RUNX2
MC 2

Coordinates (hg18)

45,946,414

433

chr6:45,946,358CTGGGATGGCCAGAGAGAGG

TGGCTTCGATATGCCTCTAGTGTA

45,946,610

253

Table 3.1. Sequences of +542RUNX2 tested for enhancer activity. Both
elements are wholly located within +542RUNX2. The primer sequences are those
used to amplify the elements from genomic DNA for testing.
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CHAPTER 4
DISCUSSION, SUMMARY AND FUTURE
DIRECTIONS
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CHAPTER 4
Summary of human RUNX2 associated enhancers
Runx2 is the common denominator in osteoblast development throughout the
skeleton, and its levels of expression are critical. As a crucial step in
understanding the regulation of the gene, and subsequently the skeleton itself, I
have identified distant osteoblast specific enhancers associated with RUNX2 and
characterized signaling pathways acting on them. Despite their common feature
of directing osteoblast expression, they are strikingly diverse. They are widely
spaced across the locus (Figure 2.1), have no obvious sequence similarity to each
other, and are conserved across species to varying degrees. While they all direct
expression to osteoblasts, they do so with differing spatiotemporal dynamics.
The cleithrum is the first bone to ossify in the zebrafish skeleton and does so
intramembraneously. Using it as a proxy for the relative timing of expression
onset yields a sequence of +542RUNX2  +210RUNX2  -460RUNX2 (Figure
2.3). Whether this is consistent across all bony structures is unclear; it appears
that the ability to drive expression to the vertebral arches is exclusively a
property of +542RUNX2 (Figure 2.6).
In addition to expression at the resolution of individual bones,
subpopulations of osteoblasts express the three transgenes differentially. As is
evidenced by study of opercle development in these transgenic lines (Figure 2.4)
these enhancers direct expression to different cells within that structure.
+542RUNX2:eGFP expression is uniform throughout the opercle and cleithrum
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(Figure 2.3). Combining these observations with its unique expression in the
vertebral arches and early expression in the cleithrum, it is intriguing to
speculate that +542RUNX2-mediated expression is the most ‘fundamental’ of the
three characterized enhancers and tied primarily to osteoblast identity itself.
The expression pattern directed by +210RUNX2 with respect to the developing
opercle is similar to that of the fli1:eGFP transgenic line, which labels all neuralcrest derived mesenchyme 161 and may indicate cells that have recently become
RUNX2+. Finally, -460RUNX2 expression is relatively strongest in the strut and
the leading edge in the fan structure of the bone. These cells are also sp7:mCh
positive, indicating their likely active deposition of bone ECM components. The
opercle fan structure expands via a banding pattern 161 , so -460RUNX2 positive
cells may be those that have committed to remaining in a specific iteration of
that process.
Finally, these three CREs do not fit the definition of redundant ‘shadow’
enhancers 174 that reinforce a response to a single inductive event and ensure
transcriptional robustness to environmental variability. Rather, they appear to
integrate inputs from different signaling pathways to induce or maintain Runx2
expression (Figure 4.1). This observation parallels and complements the
diversity of signaling inputs capable of accelerating Runx2 expression and
osteogenic differentiation in the literature.
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Summary of human RUNX2 associated enhancer activity -- +210RUNX2 directs
expression to osteoblasts separably through FGF signaling and Runx2
autoregulation.
That +210RUNX2 shares orthology both in sequence and function with an
element similarly placed in the last intron of the zebrafish Runx2 ortholog
runx2a (+154runx2a;Figure 2.5) suggests its role in regulating Runx2 activity is
ancient, and consequential. It also possesses a modularity competent to respond
to FGF signaling to direct expression to the branchial arches (essentially) or
osteoblasts (qualitatively), while also possessing a conserved binding site for
RUNX2 required to direct bone expression. The involvement for FGF signaling
during osteoblast differentiation generally has been discussed in Chapter 1, so it
is not surprising that +210RUNX2 directs expression to the calvarial sutures
that are so sensitive to that signaling axisl.
+210RUNX2 also presumably functions as a site for positive autoregulation
of Runx2 activity. In diverse biological systems, the existence of a positive
feedback loop is an essential step in the creation of switches with an all-or-none
‘digital’ output characteristic 175 . And where better to place a switch incapable of
nuance than at a gatekeeper gene whose expression above threshold is sufficient
to completely alter cell fate? Whether the +210Runx2 response to RUNX2 is a
required step in the commitment of MSCs or chondrocytes to an osteoblastic fate
is unclear. There may be other unannotated positive and negative feedback loops

l

Kague, E. Unpublished observation
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involving recruitment of RUNX2 to target CREs, to alter cell fate kinetics.
Analysis of the rat and mouse Runx2 P1 promoters indicated that RUNX2
binding to the 5’ UTR coding region of Runx2 was capable of suppressing
transcription in vitro 176 . However, a reasonable hypothesis is that +210RUNX2
functions to ‘lock in’ a cell to an osteoblastic fate commitment, due to its inability
to direct bone-specific expression without a conserved binding site.
Summary of human RUNX2 associated enhancers -- +542RUNX2 directs
expression to early osteoblasts.
Dissection of the activity of +542RUNX2 was focused on the two most
biologically likely conserved direct upstream regulators. SATB2 is a nuclear
matrix attachment protein that also functions as a transcription factor. Satb2-/mice have generalized osteoblast differentiation delays as well as craniofacial
patterning defects. Deletion of the predicted SATB2 binding site from
+542RUNX2 did not affect the ability of the enhancer to direct expression to
osteoblasts. Although, SATB2 binds the promoters of and upregulates bone
marker genes, it is also hypothesized to act as a negative regulator of Hoxa2
expression during osteoblast differentiation. Whether it might be executing a
similar role with regards to regulation of +542Runx2 is unclear with respect to
current experimental evidence.
Members of the Dlx family are dynamically expressed during osteoblast
maturation, suggesting roles in different aspects of this process 177 . During skull
formation in chick, Dlx5 is expressed in osteoblast progenitors, specifically in
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response to BMP but not FGF signaling, and its expression activates Runx2 and
osteogenic differentiation in uncommitted embryonic calvarial mesenchyme 78 .
Zebrafish dlx5a is expressed in the cleithrum at least as early as the long pec
stage (~42 HPF) 178 , consistent both with early expression of runx2b and early
activity of +542RUNX2. Coexpression of bmp2a 178 and bmp2b early in the
cleithrum is also consistent with a BMP->DLX->RUNX2 signaling axis in these
cells. However, +542RUNX2 did not demonstrate response to perturbation by
induction of bmp2b or chd via heat shock (data not shown), confounding the
impulse to arrive at such a conclusion. While the ablated binding site was
identified by multiple algorithms as one similar to others capable of recruiting
DLX proteins, transcription factor binding site profiles are famously degenerate,
and so it is reasonable that other homeodomain containing proteins could be
signaling through +542RUNX2.
Summary of human RUNX2 associated enhancers -460RUNX2 potentially links
Wnt signaling, Runx2 regulation and variation in common skeletal phenotypes
and diseases.
Although experimental and clinical data indicate that gross aberrations in
Runx2 expression cause skeletal disorders, smaller individual variations in
Runx2 dosage might be responsible for differences in variation of non-pathologic
skeletal phenotypes or susceptibility to disease. A cluster of SNPs associated
with skeletal conditions (bone mass density (BMD) and osteoarthritis (OA), and
height in three different populations) by genome wide association studies cluster
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around the Wnt responsive enhancer -460RUNX2 (Figure 4.3; Table4.1) No other
SNPs associated with skeletal phenotypes are located in the remainder of the
RUNX2 locus. Wnt signaling has been well implicated in affecting BMD,
although the precise mechanism of that effect is not clear in the literature. Some
evidence suggests the effect of Wnt signaling on bone mass is indirect, mediated
by serotonin secretion by neuroendocrine cells of the gut 179 , although this has
been disputed 180 . The presented data strongly support a direct role for Wnt
signaling in osteoblasts, acting via transcriptional regulation of Runx2.
The location of -460RUNX2 suggests that variations in the enhancer itself
alter the risk of low BMD and OA and influence height through changes in
RUNX2 expression. Interestingly, in addition to its positive association with
BMD, the canonical Wnt pathway has been implicated in increased
osteoarthritis risk 181, 182 , as has increased RUNX2 expression 183, 184 Therefore,
sequence variants in the population may affect either the basal activity of 460RUNX2 or its responsiveness to Wnt signaling, accounting for the genetic
associations with both of these skeletal phenotypes. An intriguing possibility is
that two alleles at a single location could lead either to increased enhancer
activity and increased arthritis risk, or decreased enhancer activity and
increased risk of osteoporosis.
Runx2 expression modulation as a source of evolutionary skeletal diversity.
Runx2 protein activity is positively correlated to facial length in carnivores,
especially domesticated dogs 185 . This relationship is not generally true among
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placental mammals, suggesting that other changes, such as in gene expression
levels, are more likely to correlate with intra– or inter-specific variation 186 . The
sensitivity of normal skeletal development to precise levels of Runx2 has led to
the suggestion that alterations in Runx2 activity provide a mechanism for
skeletal evolution, acting as a ‘tuning knob’ to either accelerate or delay
osteoblast differentiation during development 186 . Following assembly of the
Neanderthal genome sequence, the RUNX2 locus was identified as one of the
regions with the strongest evidence of positive selection in the evolution of
modern humans 187 . Specifically, the 3' end of RUNX2, encompassing
+210RUNX2, shows a deficit of derived alleles in modern humans (Figure 4.3a).
No fixed differences in the RUNX2 coding sequence are present between
Neanderthal and modern humans, suggesting that the positive selection has
acted on changes in regulatory sequences. Comparing the human +210RUNX2
sequence to other primates identifies three derived, human specific SNPs that
could potentially link this element to the evolution of the human skeleton
(Figure 4.3b). Interestingly, many of the differences between the skeletons of
Neanderthal and modern humans—clavicular morphology, frontal bossing of the
skull—are similar to the differences observed in cleidocranial dysplasia, which is
caused by a Runx2 gene dosage defect 127, 188, 189 .
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Future directions
Future investigation of the functional consequences of specific sequence
alterations in the RUNX2 enhancers will shed light on the role of its regulation
in development, evolution, and disease. An obvious question resulting from the
screen in Chapter 2 is the thoroughness of it. While it is likely impossible to ever
know the cis regulatory architecture of single gene in a complex eukaryotic
genome has been exhaustively annotated, some potential experiments in other
model systems present themselves to address this question. However, this will
require divesting ourselves of the zebrafish model. While it has been shown to be
an effective system for evaluating the regulatory potential of discrete elements in
the human genome, the existence of two runx2 genes as well as the current size
limitations of BAC-mediated transgenesis make the fish a poor choice to study
the intact human Runx2 locus. To try to get a broader locus-wide view of Runx2
enhancer dynamics during development, we must turn turn to a system with a
more similar Runx2 structure, namely the mouse.
Although not discussed in this document, it is not difficult to obtain a
population of cells uniformly positive for the Runx2 transgene from early
embryos. This process necessitates enzymatic digestion followed by flowcytometry sorting to derive an enriched population of transgene expressing
osteoblasts at a relatively discrete stage of development. Sorting based on
multiple colors/transgenes can further refine this staging. Creating one or more
mouse transgenic lines using either the +542RUNX2 or -460RUNX2 elements
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would, assuming expression patterns are similar in the mouse, permit
exploration for bone specific enhancers in early osteoblasts. This could be done
by looking for enrichment for histone modifications associated with regulatory
sequences, or for regions directly associated with RUNX2 itself. Circular
chromosome conformation capture (4C) allows to us to ask questions specifically
about the dynamics of the Runx2 locus itself. Using one or both Runx2 promoters
as ‘bait’, comparing the physical interaction of distal elements with the Runx2
TSS would presumably yield a list of currently unknown cis regulators, as well
as informing how they and the currently known Runx2 enhancers function
dynamically through osteoblast development189.
Additionally, as the number of and knowledge regarding individual RUNX2
cis regulators grows, the genetic tools they offer might be applicable to studying
bone biology in other contexts than embryonic differentiation. +210RUNX2
transgenic fish have already been used in a to study bone regeneration postamputation 190 as well as suture development in the skull vaultm. Certainly, how
bones heal post-fracture is a robust area of research 191 , and the ability to
visualize Runx2 expression during in vivo assays would presumably augment
them. Finally, the transgenic lines could be incorporate in a high throughput
screen against a pharmaceutical library 192 , enhancing drug discovery for Runx2
expression mediators that may aid in therapies for common skeletal disorders
such as OA and osteoporosis.

m

E. Kague, unpublished
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Conclusion
Taken together, the data presented in this document provide evidence for
direct regulation of Runx2 transcription by biologically important signaling
pathways and transcription factors through three independent enhancers. This
complex regulatory landscape has allowed the fine–tuning of expression of this
critical developmental gene through alterations in enhancer activities.
Furthermore, I hypothesize that these alterations have been selected for in
evolution, and help account for differences in skeletal morphology among species.
This data also supports the model that variations in a distal enhancer of RUNX2
account for genetic associations in the region with height, BMD, and increased
OA risk.
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Figure 4.1 -- Model for integration of multiple signaling inputs at the
Runx2 locus. Three identified enhancers at the Runx2 locus are regulated by
different upstream factors, and each is capable of interacting independently with
the transcriptional start site (dotted lines) to activate gene transcription. Once
transcription is activated via one or more external signals, it is stabilized by
Runx2 auto-regulation through the intronic enhancer. Downstream, expression
of Runx2 in mesenchymal precursor cells of diverse embryologic origins leads to
activation of genes necessary for development of osteoblasts.
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Figure 4.2 – SNPs associated with skeletal phenotypes and disorders
cluster near the Wnt responsive enhancer -460RUNX2. A genome browser
view of the human RUNX2 locus interrogated for regulatory activity shows the
location of all SNPs associated with a human phenotype by genome wide
association studies. SNPs associated with skeletal phenotypes are listed in Table
4.1; rs1932040 is associated with attention deficit hyperactivity disorder.
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Figure 4.3 – Recent positive selection in the human lineage near
+210RUNX2. (a) Genome browser view of the human RUNX2 locus. Signals of
positive selection based on scoring of individual SNPs. A negative score indicates
more derived alleles in modern humans relative to Neanderthals and is evidence
of positive selection. SNP scan data obtained from

187

. (b) Three derived SNPs

(indicated by red rectangles) in +210RUNX2 are candidate alleles for a recent
selective sweep in the human lineage. All three are derived with respect to the
ancestral primate state and have not been observed to be polymorphic in human
populations.
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SNP

Phenotype

MAF

Dist from -460RUNX2 (kb)

rs556621

Atherosclerotic Stroke

0.3

-241

rs11755164

Bone mass density

0.4

-196

rs10948172

Osteoarthritis

0.29

58

rs9472414

Adult Height (European)

0.22

111

rs10948197

Adult Height (Korean)

0.34

132

rs9395066

Adult Height (DECODE)

0.48

260

Table 4.1 – SNPs associated with human skeletal phenotypes in the human
RUNX2 locus. Minor allele frequency is given in the studied population. Distance
from the Wnt responsive enhancer -460RUNX2 is given in kilobases. A negative
distance indicates distance 5’ to the element, while a positive one denotes 3’
separation.
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